id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-306595-ru725fbr	Ammor, Othmane	Hidroxicloroquina / cloroquina y azitromicina en pacientes con COVID-19: estudio prospectivo de parámetros eléctricos	2020-09-11		.txt	text/plain	862	65	59	All hospitalized patients with PCR-confirmed COVID-19 infection treated with chloroquine/hydroxychloroquine plus azithromycin were included from April 7 to May 6. PCR-confirmed COVID-19 patients were treated as follows: chloroquine (500 mg twice a day for 10 days) or hydroxychloroquine (200 mg 3 times a day, for 10 days) in combination with azithromycin (500 mg on day 1, then 250 mg a day from day 2 to 7). In our study, the association of chloroquine/hydroxychloroquine and azithromycin induced significant QTc prolongation in 33 of 87 patients (38%), but a severe prolongation was noted in only 13 (15%) patients (QTc > 500 ms or delta QTc > 60ms). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin	./cache/cord-306595-ru725fbr.txt	./txt/cord-306595-ru725fbr.txt